5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers
Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.
PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes
The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Darolutamide/ADT Improves rPFS in Metastatic HSPC
Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
Radiotherapy/CAR T Combo May be “Great Option” in Relapsed/Refractory DLBCL
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma
P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.
Bridging Radiation and CAR T-cell Therapy May Have Benefit in Relapsed/Refractory DLBCL
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC
Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Getting to the CAR T-cell Therapy Starting Line With Radiotherapy in R/R DLBCL
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Nadunolimab Combo Shows Promising Efficacy in Advanced/Metastatic PDAC
Results from the CANFOUR trial of combining nadunolimab with chemotherapy appear to prolong overall survival among those with advanced or metastatic PDAC.
Metabolic-Bariatric Surgery Reduces Pancreatic Cancer Risk in Obese Group
Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.
Stereotactic Radiosurgery/TKIs Improves CNS Outcomes in EGFR/ALK+ NSCLC
Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Overcoming Barriers to Trial Enrollment and Gaps in Gynecologic Cancer Care
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC
Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Durvalumab Shows Manageable Safety Profile in LS-SCLC
Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.
Advancing Prevention and Genetic Testing Methods in Uterine Cancer
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued
TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.
Raising Awareness to Address the Rising Incidence of Gynecologic Cancers
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC
Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.
Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM
Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.
Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLC
James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Uterine Transposition Surgery Improves QOL Through Fertility Preservation
A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.
PFS Benefit Occurs with Complete vs Incomplete Consolidative RT in ES-SCLC
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC
Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.
Assessing Consolidative Radiation in Extensive-Stage Small Cell Lung Cancer
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Neoadjuvant/Adjuvant Pembrolizumab Combo Improves OS in NSCLC
Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.
Data Show Disease Control With Inavolisib in Advanced PIK3CA+ Solid Tumors
Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.
Durcabtagene Autoleucel Yields Responses in Relapsed/Refractory Myeloma
Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.
